Thus, this ASO approach in combination with current CF drugs offers a potential therapeutic for individuals with the CFTR-W1282X mutation and opens the door for similar strategies to treat other terminating mutations, both in CF and other diseases. This evidence concerns the gene CFTR and cystic fibrosis.